US Corporate Distress Financial Stress SEC Filings — October 29, 2026

29-10-2026

Cullen/Frost Bankers notified the NYSE on October 29, 2026 of its intention to voluntarily delist its Common Stock (CFR) and 4.450% Series B Preferred Depositary Shares (CFR.PrB) and transfer both listings to the Texas Stock Exchange (TXSE). NYSE trading is expected to end at market close on November 11, 2026, with TXSE trading beginning at market open on November 12, 2026, retaining the same symbols. The move was board-authorized and is a voluntary exchange transfer rather than a delisting for failure to meet listing standards.

• · Filing is on Form 8-K under Items 3.01, 7.01 and 9.01
• · Company is incorporated in Texas; Commission File Number 001-13221; IRS EIN 74-1751768
• · Principal executive offices: 111 W. Houston Street, San Antonio, Texas 78205
• · Both securities will retain the same ticker symbols (CFR and CFR.PrB) on TXSE
• · Press release issued October 29, 2026 furnished as Exhibit 99.1; cover page XBRL as Exhibit 104
• · Filing signed by Daniel J. Geddes, Group EVP and CFO, dated October 29, 2026
• · Company is not an emerging growth company

29-10-2026

Propanc Biopharma received a Nasdaq notice on October 23, 2026 that it is not in compliance with the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2), based on the closing bid price over the 30 consecutive business days prior to October 21, 2026. Because the company had already effected a reverse stock split within the prior one-year period, it is ineligible for the standard 180-calendar day compliance period under Rule 5810(c)(3)(A)(iv), and its securities face delisting on November 2, 2026 unless it appeals by October 30, 2026. The company intends to appeal, believing it has cured the deficiency, though it acknowledges delisting would reduce liquidity, shrink its investor base, limit access to public capital markets, and impair its ability to grant equity incentives.

• · Delisting would take effect November 2, 2026 absent an appeal
• · Appeal deadline is October 30, 2026; an appeal stays the delisting pending the Panel's decision
• · Receipt of the Notice does not affect the company's business, operations, or SEC reporting requirements
• · Company is incorporated in Delaware, Commission File Number 001-42806, IRS EIN 33-0662986
• · Principal executive office is at 302, 6 Butler Street, Camberwell, VIC, 3124, Australia
• · Company is not an emerging growth company

29-10-2026

TB Alternative Assets Ltd. and related Reporting Persons filed Amendment No. 3 to Schedule 13D, the final amendment, reporting that following the merger of Cloopen Group Holding Limited (RAASY) with Merger Sub (effective October 28, 2026), the Reporting Persons no longer beneficially own any Ordinary Shares or ADSs and have ceased to be beneficial owners of more than 5% of the Issuer's shares. The Issuer became a privately held, wholly-owned subsidiary of HoldCo, its ADSs will no longer be quoted on the OTC Pink Market, and the ADS program will be terminated.

• · The EGM was held on September 24, 2026; the Merger was effective October 28, 2026 upon registration with the Cayman Islands Registrar of Companies
• · Excluded Shares were cancelled without consideration; Dissenting Shares are entitled only to fair value under Section 238 of the Companies Act (As Revised) of the Cayman Islands
• · The Issuer intends to file Form 15 with the SEC to suspend Exchange Act reporting obligations
• · Reporting Persons reported zero beneficial ownership as of October 28, 2026, and no transactions in the prior 60 days beyond those previously disclosed
• · Original Schedule 13D was filed December 30, 2025, with Amendment No. 1 on May 13, 2026 and Amendment No. 2 on July 31, 2026

29-10-2026

Greenland Energy Company (GLND) disclosed in an 8-K that following the October 20, 2026 resignation of director Roderick McIllree, it notified Nasdaq on October 23, 2026 that it fell out of compliance with Nasdaq Listing Rule 5605(b)(1) (majority independent director requirement) and Rule 5605(c)(2)(A) (three independent directors on the audit committee). Nasdaq issued a letter dated October 28, 2026 granting a cure period until the earlier of the next annual shareholders' meeting or October 20, 2027 (or April 19, 2027 if the annual meeting is held before that date); however, the audit committee deficiency was already cured on October 27, 2026 when the Board appointed independent director Melanie Furlan, joining Scott Wollney and Carol Craig. The company says there is no immediate effect on its Nasdaq listing, with common stock (GLND) and warrants (GLNDW) continuing to trade on the Nasdaq Global Market, though the majority independent director deficiency remains outstanding.

• · McIllree resigned from the Board and all assignments with the Company on October 20, 2026
• · Nasdaq cure period runs until the earlier of the next annual shareholders' meeting or October 20, 2027; if the annual meeting occurs before April 19, 2027, compliance must be evidenced by April 19, 2027
• · The audit committee deficiency under Rule 5605(c)(2)(A) was cured on October 27, 2026 via Furlan's appointment
• · The majority independent director deficiency under Rule 5605(b)(1) remains uncured as of the filing
• · Company is a Texas corporation, commission file number 001-43210, IRS EIN 39-4828593, headquartered at 3400 East Bayaud Avenue, Suite 400, Denver, Colorado 80209
• · Company qualifies as an emerging growth company
• · 8-K signed by CEO Robert Price on October 29, 2026

29-10-2026

Glucotrack, Inc. (GCTK) received written notice from a Nasdaq Hearings Panel on October 28, 2026, determining to delist its securities because its closing bid price was $0.87 on October 14, 2026, failing to satisfy the terms of a previously granted exception to the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Trading in the common stock will be suspended at the open on October 30, 2026, and Nasdaq is expected to file a Form 25 to delist and deregister the shares under Section 12(b). The company plans to have its shares quoted on the OTC Markets OTCID tier upon suspension, though no assurance of that transition is provided.

• · Nasdaq Hearings Panel exception was conditioned on maintaining a closing bid price of at least $1.00 for each trading day through November 9, 2026
• · Trading suspension takes effect at the open of trading on October 30, 2026
• · Company intends to submit an application to trade on the OTCID Market of OTC Markets Group
• · Risk Factors referenced in the Annual Report on Form 10-K filed with the SEC on March 30, 2026
• · Company is not an emerging growth company (box unchecked)